



04 JUN 2021

**FDA ADVISORY**  
No. **2021-1207**

**TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT : Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:**

1. Metformin Hydrochloride Tablets 0.25g [Label in Foreign Language]
2. OTC Vitamin E Soft Capsules
3. A.T.P. Adenosine Disodium Triphosphate Tablets 20 mg
4. Xinnaokang Jiaonang 0.25g [as reflected in the package insert]
5. Shiduoqingruangao

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:







OTC Vitamin E Soft Capsules

Figure 2. Unregistered drug product



A.T.P. Adenosine Disodium Triphosphate Tablets 20 mg

Figure 3. Unregistered drug product



密之康® [批准文号] 国药准字Z22025480

# 心脑康胶囊

【功能主治】活血化瘀，通窍止痛。用于瘀血阻络所致的胸痹、眩晕、症见胸闷、心前区刺痛、眩晕、头痛；冠心病心绞痛、脑动脉硬化见上述证候者。

吉林省密之康药业有限责任公司  
JILINSHENGMIZHIKANGYAOYEOUXIANZERENGONGSI



**Xinnaokang Jiaonang 0.25g [as reflected in the package insert]**  
by: Jilinshengmizhikangyaoeyouxianzerengongsi

Figure 4. Unregistered drug product

非凡人®

# 湿毒清软膏

SHIDUQINGRUANGAO

请仔细阅读使用说明书并按说明使用或在指导下购买和使用

- 金黄色葡萄球菌
- 白色念珠菌
- 大肠杆菌

江西非凡生物科技有限公司



**Shiduqingruangao**

Figure 5. Unregistered drug product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee its quality, safety and efficacy. Therefore, consumption of such violative products may pose potential danger or injury to health.


Pursuant to Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at [info@fda.gov.ph](mailto:info@fda.gov.ph). To report continuous sale or distribution of unregistered health products, kindly e-mail us via [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph). You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.

  
ROLANDO ENRIQUE D. DOMINGO, MD  
Director General

DTN:



20210527074246